New pill PG-033 tested for safety in first human trial
NCT ID NCT07619183
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial will test the safety and tolerability of multiple doses of PG-033 tablets in 30 healthy adults. Participants will be randomly assigned to receive either PG-033 or a placebo. The study aims to find out how the drug moves through the body and whether it causes any side effects. If successful, it could lead to further research on PG-033 as a treatment for lichen simplex chronicus, a condition that causes intense itching and thickened skin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PG-033 tablets
What this could lead to
If this early safety study goes well, it could pave the way for larger trials testing PG-033 as a treatment for lichen simplex chronicus, a chronic itchy skin condition.
What could go wrong
This is a very early Phase 1 trial with only 30 healthy participants, so it cannot yet show if PG-033 actually helps the disease. The drug may prove unsafe or ineffective in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LICHEN SIMPLEX CHRONICUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Shijitan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100038, China